{"session_id": 21, "bill_id": 6403, "bill_type": "Senate Bill", "bill_number": 61, "bill_title": "place certain substances on the controlled substances schedule and to declare an emergency.", "sponsors": [], "keywords": ["Drugs And Substances Control", "Public Health and Safety"], "audio": [{"meeting_datetime": "2015-01-21T00:00:00-06:00", "committee": "SHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/she06.mp3", "start_seconds": 115.0}, {"meeting_datetime": "2015-01-21T00:00:00-06:00", "committee": "SHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/she06.mp3", "start_seconds": 115.0}, {"meeting_datetime": "2015-01-21T00:00:00-06:00", "committee": "SHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/she06.mp3", "start_seconds": 115.0}, {"meeting_datetime": "2015-01-22T00:00:00-06:00", "committee": "SEN", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/sen07.mp3", "start_seconds": 1759.0}, {"meeting_datetime": "2015-01-22T00:00:00-06:00", "committee": "SEN", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/sen07.mp3", "start_seconds": 1759.0}, {"meeting_datetime": "2015-01-22T00:00:00-06:00", "committee": "SEN", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/sen07.mp3", "start_seconds": 1759.0}, {"meeting_datetime": "2015-01-29T00:00:00-06:00", "committee": "HHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/hhe12.mp3", "start_seconds": 5135.0}, {"meeting_datetime": "2015-01-29T00:00:00-06:00", "committee": "HHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/hhe12.mp3", "start_seconds": 5135.0}, {"meeting_datetime": "2015-01-29T00:00:00-06:00", "committee": "HHE", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/hhe12.mp3", "start_seconds": 5135.0}, {"meeting_datetime": "2015-02-10T00:00:00-06:00", "committee": "HOU", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/hou19.mp3", "start_seconds": 8265.0}, {"meeting_datetime": "2015-02-10T00:00:00-06:00", "committee": "HOU", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/hou19.mp3", "start_seconds": 8265.0}, {"meeting_datetime": "2015-02-10T00:00:00-06:00", "committee": "HOU", "url": "https://sdpb.sd.gov/sdpbpodcast/2015/hou19.mp3", "start_seconds": 8265.0}], "bill_versions": [{"bill_id": 6403, "bill_version_id": 33036, "bill_version": "Introduced", "bill_version_date": "2015-01-10T12:32:37.1-06:00", "bill_text": "FOR AN ACT ENTITLED, An Act to place certain substances on the controlled substances schedule and to declare an emergency. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA: Section 1. That \u00a7 34-20B-14 be amended to read as follows: 34-20B-14. Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Bufotenine; (2) Diethyltryptamine (DET); (3) Dimethyltryptamine (DMT); (4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT); (5) 5-methoxy-3, 4-methylenedioxy amphetamine; (6) 4-bromo-2, 5-dimethoxyamphetamine; (7) 4-methoxyamphetamine; (8) 4-methoxymethamphetamine; (9) 4-methyl-2, 5-dimethoxyamphetamine; (10) Hashish and hash oil; (11) Ibogaine; (12) Lysergic acid diethylamide; (13) Mescaline; (14) N-ethyl-3-piperidyl benzilate; (15) N-methyl-3-piperidyl benzilate; (16) 1-(-(2-thienyl)cyclohexyl) piperidine (TCP); (17) Peyote, except that when used as a sacramental in services of the Native American church in a natural state which is unaltered except for drying or curing and cutting or slicing, it is hereby excepted; (18) Psilocybin; (19) Psilocyn; (20) Tetrahydrocannabinol, other than that which occurs in marijuana in its natural and unaltered state, including any compound, except nabilone or compounds listed under a different schedule, structurally derived from 6,6. dimethyl-benzo[c]chromene by substitution at the 3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups, whether or not the compound is further modified in any of the following ways: (a) By partial to complete saturation of the C-ring; or (b) By substitution at the 1-position with a hydroxyl or methoxy group; or (c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl group; or (d) By modification of the possible 3-alkyl group with a 1,1. dimethyl moiety, a 1,1. cyclic moiety, an internal methylene group, an internal acetylene group, or a terminal halide, cyano, azido, or dimethylcarboxamido group. Some trade and other names: JWH-051; JWH-057; JWH-133; JWH-359; HHC; AM-087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243; HU-336; (21) 3, 4, 5-trimethoxy amphetamine; (22) 3, 4-methylenedioxy amphetamine; (23) 3-methoxyamphetamine; (24) 2, 5-dimethoxyamphetamine; (25) 2-methoxyamphetamine; (26) 2-methoxymethamphetamine; (27) 3-methoxymethamphetamine; (28) Phencyclidine; (29) 3, 4-methylenedioxymethamphetamine (MDMA); (30) 3, 4-methylenedioxy-N-ethylamphetamine; (31) N-hydroxy-3, 4-methylenedioxyamphetamine; (32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline); (33) 2,5 Dimethoxy-4-ethylamphetamine; (34) N,N-Dimethylamphetamine; (35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; (36) Aminorex; (37) Cathinone and other variations, defined as any compound, material, mixture, preparation or other product unless listed in another schedule or an approved FDA drug (e.g. buproprion, pyrovalerone), structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways: (a) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substitutents; (b) By substitution at the 3-position with an acyclic alkyl substituent; (c) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic structure. Some trade or other names: methcathinone, 4-methyl-N-methylcathinone (mephedrone); 3,4-methylenedioxy-N-methylcathinone (methylone); 3,4-methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4-flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-PMMA); Ethcathinone (N-Ethylcathinone); 3,4-methylenedioxyethcathinone (ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N-dimethylcathinone (metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-PPP); 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4-methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha-pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4.-Methyl-alpha-pyrrolidinobutiophenone (MPBP); Methyl-.-pyrrolindinopropiophenone (MPPP); Methyl-.-pyrrolidino-hexanophenone (MPHP); Buphedrone; Methyl-N-ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC); Dimethylethcathinone (DMEC); Methylenedioxymethcathinone (MDMC); Pentylone; Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl-alpha-pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC); Methylbuphedrone (MBP); Benzedrone (4-MBC); Dibutylone (DMBDB); Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N-ethyl-N-Methylcathinone; N-ethylbuphedrone; (38) 2,5-Dimethoxy-4-ethylamphetamine (DOET); (39) Alpha-ethyltryptamine; (40) 4-Bromo-2,5-dimethoxy phenethylamine; (41) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7); (42) 1-(3-trifluoromethylphenyl) piperazine (TFMPP); (43) Alpha-methyltryptamine (AMT); (44) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); (45) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); (46) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is not listed as a controlled substance in another schedule, is not an FDA-approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues, modifications of the indole ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog substitution of the phenyl, benzyl, naphthyl, adamantly, cyclopropyl, cumyl, or propionaldehyde structure, and salts of isomers and, homologues, and modifications, unless specifically excepted, whenever the existence of these salts, isomers, homologues, modifications, and salts of isomers and, homologues, and modifications is possible within the specific chemical designation: (a) Naphthoylindoles. Any compound containing a 2-(1-naphthoul)indole or 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N- methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted in on the indole ring to any extent and whether or not substituted in on the naphthyl ring to any extent. Some trade or other names: JWH-015; 1-pentyl-3-(1-naphthoyl)indole (JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398; 1-pentyl-3-(1-naphthoyl)indole (AM-678); 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009; JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048; JWH-049; JWH-050; JWH-070; JWH-071; JWH_072; JWH-076; JWH-079; JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120; JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182; JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234; JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262; JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400; JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220; AM-1221; AM-1235; AM-2232; (b) Naphthylmethylindoles. Any compound containing a 1H-indol-2-yl-(1-naphthyl)methane or 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran- 4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted in on the indole ring to any extent and whether or not substituted in on the naphthyl ring to any extent. Some trade or other names: JWH-175; JWH-184; JWH-185; JWH-192; JWH-194; JWH-195; JWH-196; JWH-197; JWH-199; (c) Phenylacetylindoles. Any compound containing a 2-phenylacetylindole or 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted in on the indole ring to any extent and whether or not substituted in on the phenyl ring to any extent. Some trade or other names: 1-cyc lohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8); 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-316; Cannabipiperidiethanone; (d) Benzoylindoles. Any compound containing a 2-(benzoyl)indole or 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted in on the indole ring to any extent and whether or not substituted in on the phenyl ring to any extent. Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline (WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630; AM-661; AM-2233; AM-1241; (e) Naphthoylpyrroles. Any compound containing a 2-(1-naphthoyl)pyrrole or 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted in on the pyrrole ring to any extent and whether or not substituted in on the naphthyl ring to any extent. Some trade or other names: JWH-307; JWH-030; JWH-031; JWH-145; JWH-146; JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244; JWH-245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346; JWH-348; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369; JWH-370; JWH-371; JWH-373; JWH-392; (f) Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran- 4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted in on the indene ring to any extent and whether or not substituted in on the naphthyl ring to any extent. Some trade or other names: JWH-171; JWH-176; JWH-220; (g) Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not substituted in on the cyclohexyl ring to any extent. Some trade or other names: 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes C8); cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667; (h) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names: HU-210; (I) 2,3-Dihydro-5-methyl-3-(4-m orpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenyl. Some trade or other names: WIN 55, 212-2; (j) Substituted Acetylindoles. Any compound containing a 2-acetyl indole or 3-acetyl indole structure substituted at the acetyl with a tetramethylcyclopropyl, adamantyl, or benzyl, cumyl, or propionaldehyde substituent whether or not further substituted in on the tetramethylcyclopropyl, adamantyl, or benzyl, cumyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted in on the indole ring to any extent. Some trade and or names: (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144); (1-(5-fluoropentyl)indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11); (1-(2-morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (A-796,260); 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole (AM-1248); 1-Pentyl-3-(1-adamantoyl)indole (AB-001 and JWH-018 adamantyl analog); AM-679; (k) Substituted Carboxamide Indole. Any compound containing a 2-carboxamide indole or 3-carboxamide indole structure substituted at the carboxamide with a tetramethylcyclopropyl, naphthyl, or adamantyl, cumyl, or propionaldehyde substituent, whether or not further substituted in on the tetramethylcyclopropyl, or adamantyl, cumyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,or (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted in on the indole ring to any extent. Some trade and other names: JWH-018 adamantyl carboxamide; STS-135; MN-18; 5-Fluoro-MN-18; (l) Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent whether or not further substituted on the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group whether or not further substituted on the indole ring to any extent; (47) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI); (48) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); (49) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); (50) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); (51) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); (52) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); (53) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); (54) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); (55) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); (56) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); (57) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from phenylethan-2-amine by substitution on the phenyl ring in any of the following ways, that is to say--by substitution with a fused methylenedioxy, fused furan, or fused tetrahydrofuran ring system; by substitution with two alkoxy groups; by substitution with one alkoxy and either one fused furan, tetrahydrofuran, or tetrahydropyran ring system; by substitution with two fused ring systems from any combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems; whether or not the compound is further modified in any of the following ways: (a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl, alkoxy, or alkylthio groups; (b) By substitution on the 2-position by any alkyl groups; or (c) By substitution on the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, methoxybenzyl, or hydroxybenzyl groups. Some trade and other names: 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine (2C-T or 4-methylthio-2,5-dimethoxyphenethylamine); 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI or 2, 5-Dimethoxy-4-iodoamphetamine); 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB or 2,5-Dimethoxy-4-bromoamphetamine); 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC or 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-B-NBOMe; 25B-NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2-4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-I-NBOMe; 25I-NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N.(2-Methoxybenzyl)-2-(3,4,5-trimethoxypheny (Mescaline-NBOMe or 3,4,5-trimethoxy-_(2-methoxybenzyl)phenethylamine); 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-C-NBOMe; 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine); 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY); 2-(8- bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY); 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-yl)ethanamine (2C-B-butterFLY); _(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b.]difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe); 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (bromo-benzodifuranyl-isopropylamine or bromo-dragonFLY); _(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine (2C-I-NBOH or 25I-NBOH); 5-(2-Aminoprpyl)benzofuran (5-APB); 6-(2-Aminopropyl)benzofuran (6-APB); 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB); 6-(2-Aminopropyl)-2,3,-dihydrobenzofuran (6-APDB); (58) Substituted tryptamines. Any compound, unless specifically exempt, listed as a controlled substance in another schedule or an approved FDA drug, structurally derived from 2-(1H-indol-3-yl)ethanamine (i.e, tryptamine) by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a cyclic structure whether or not the compound is further substituted at the alpha-position with an alkyl group or whether or not further substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups. Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT); (59) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13); (60) N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48); (61) 1-(4-Fluorophenyl)piperazine (pFPP); (62) 1-(3-Chlorophenyl)piperazine (mCPP); (63) 1-(4-Methoxyphenyl)piperazine (pMeOPP); (64) 1,4-Dibenzylpiperazine (DBP); (65) Isopentedrone; (66) Fluoromethamphetamine; (67) Fluoroamphetamine; (68) Fluorococaine; (69) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22); (70) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5 Fluoro-PB-22); (71) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA); (72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5 Fluoro-AB-PINACA); (73) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); (74) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADB-PINACA (ADBICA)); (75) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5 Fluoro-ADB-PINACA (5 Fluoro-ADBICA)); and (76) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA). Section 2. That \u00a7 34-20B-16 be amended to read as follows: 34-20B-16. Any of the following substances including their salts, isomers, and salts of isomers is included in Schedule II except those narcotic drugs listed in other schedules whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium (except when it meets the requirements of subdivision 34-20B-23(7) or 34-20B-26(5)), coca leaves, and opiate; (2) Any salt, compound, derivative, or preparation of opium, coca leaves (including cocaine), or opiate, excluding apomorphine, dextrorphan, and naloxone; (3) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in subdivisions (1) and (2), except that these substances may not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; and may not include the isoquinoline alkaloids of opium; (4) Opium poppy and poppy straw; (5) Amphetamine; (6) Methamphetamine; (7) Amobarbital; (8) Pentobarbital; (9) Secobarbital; (10) Methylphenidate; (11) Phenmetrazine; (12) Etorphine; (13) Diprenorphine; (14) Deleted by SL 2000, ch 170, \u00a7 1; (15) Nabilone; (16) Glutethimide; (17) Phencyclidine immediate precursors: (a) 1-phenylcyclohexylamine; (b) 1-piperidinocyclohexanecarbonitrile (PCC); (18) Lisdexamfetamine, its salts, isomers, and salts of its isomers; (19) Tapentadol; and (20) Ioflupane. Section 3. That \u00a7 34-20B-17 be amended to read as follows: 34-20B-17. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, is included in Schedule II, unless specifically excepted, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: (1) Alphaprodine; (2) Anileridine; (3) Bezitramide; (4) Diphenoxylate; (5) Fentanyl; (6) Isomethadone; (7) Levomethorphan; (8) Levorphanol; (9) Metazocine; (10) Methadone; (11) Methadone-intermediate, 4-cyano-2-dimethylamine-1, 4-diphenyl butane; (12) Moramide-intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid; (13) Pethidine; (14) Pethidine-intermediate, A, 4-cyano-1-methyl-4-phenylpiperidine; (15) Pethidine-intermediate, B, ethyl-4-phenylpiperidine-4-carboxylate; (16) Pethidine-intermediate, C, 1-methyl-4-phenylpiperidine-4-carboxylic acid; (17) Phenazocine; (18) Piminodine; (19) Racemethorphan; (20) Racemorphan; (21) Sufentanil; (22) Alfentanil; (23) Carfentanil; (24) Levo-alphacetylmethadol, also known as levo-alpha-acetylmethadyl acetate or LAAM; (25) Remifentanil; (26) Oxymorphone; (27) Oripavine (3-O-demethylthebaine or 6,7,8,14-tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methylmorphinan-3-ol); (28) 4-anilino-N-phenethyl-4-piperidine (ANPP); (29) Morphine, except when it meets subdivision 34-20B-23(8); (30) Hydrocodone (Dihydrocodeinone); (31) Codeine, except when it meets subdivision 34-20B-23(1), 34-20B-23(2), or 34-20B-26(1); (32) Dihydrocodeine, except when it meets subdivision 34-20B-23(5) or 34-20B-26(2); (33) Ethylmorphine, except when it meets subdivision 34-20B-23(6) or 34-20B-26(3); (34) Oxycodone; and (35) Hydromorphone. Section 4. That \u00a7 34-20B-23 be amended to read as follows: 34-20B-23. Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof is included in Schedule III: (1) Not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of isoquinoline alkaloid of opium.; (2) Not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.; (3) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of isoquinoline alkaloid of opium. (4) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts. (5) Not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.; (6) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.; (7) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.; and (8) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts. Section 5. That \u00a7 34-20B-25 be amended to read as follows: 34-20B-25. The following are included in Schedule IV: (1) Chlordiazepoxide, but not including librax (chlordiazepoxide hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and water soluble esterified estrogens); (2) Clonazepam; (3) Clorazepate; (4) Diazepam; (4A) Flunitrazepam; (5) Flurazepam; (6) Mebutamate; (7) Oxazepam; (8) Prazepam; (9) Lorazepam; (10) Triazolam; (11) Any substance which contains any quantity of a benzodiazepine, or salt of benzodiazepine, except those substances which are specifically listed in other schedules; (11A) Alprazolam; (11B) Midazolam; (11C) Temazepam; (12) Repealed by SL 2003, ch 183, \u00a7 4; (13) Cathine; (14) Fencamfamine; (15) Fenproporex; (16) Mefenorex; (17) Pyrovalerone; (18) Propoxyphene; (19) Pentazocine; (20) Diethylpropion; (21) Ethchlorvynol; (22) Ethinamate; (23) Fenfluramine; (24) Mazindol; (25) Mephobarbital; (26) Methohexitol; (27) Paraldehyde; (28) Pemoline; (29) Petrichloral; (30) Phentermine; (31) Barbital; (32) Phenobarbital; (33) Meprobamate; (34) Zolpidem; (35) Butorphanol; (36) Modafinil, including its salts, isomers, and salts of isomers; (37) Sibutramine; (38) Zaleplon; (39) Dichloralphenazone; (40) Zopiclone (also known as eszopiclone), including its salts, isomers, and salts of isomers; (41) Pregabalin; (42) Lacosamide; (43) Fospropofol, including its salts, isomers, and salts of isomers; (44) Clobazam; (45) Carisoprodol, including its salts, isomers, and salts of isomers; (46) Ezogabine,[_[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester], including its salts, isomers, and salts of isomers; and (47) Lorcaserin, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; (48) Alfaxalone, 5[alpha]-pregnan-3[alpha]-ol-11,20-dione, including its salts, isomers, and salts of isomers; (49) Tramadol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers; and (50) Suvorexant, including its salts, isomers, and salts of isomers. Section 6. That \u00a7 34-20B-26 be amended to read as follows: 34-20B-26. Any compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs is included in Schedule IV which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than those possessed by the narcotic drug alone: (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.; (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.; (3) Not more than 50 milligrams of ethylmorphine per 100 milliliters or per 100 grams.; (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.; (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams, or not more than 5 milligrams per dosage unit.; and (6) Not more than 0.5 milligrams 1 milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. (7) Repealed by SL 1990, ch 270, \u00a7 3. Section 7. Whereas, this Act is necessary for the immediate preservation of the public peace, health, or safety, an emergency is hereby declared to exist, and this Act shall be in full force and effect from and after its passage and approval."}, {"bill_id": 6403, "bill_version_id": 34864, "bill_version": "Enrolled", "bill_version_date": "2015-02-11T10:06:31.343-06:00", "bill_text": ""}], "amendments": [], "fiscal_notes": [166076], "action_log": [{"bill_id": 6403, "action_date": "2015-01-13T12:00:00-06:00", "document_id": 33120, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/33120.pdf", "status_text": "First read in Senate and referred to", "journal_page": 27, "committee_id_action": 284, "committee_id_assigned": 264, "result": "N", "vote": {}}, {"bill_id": 6403, "action_date": "2015-01-21T10:00:00-06:00", "document_id": 33218, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/33218.pdf", "status_text": "Scheduled for hearing", "journal_page": 0, "committee_id_action": 264, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 6403, "action_date": "2015-01-21T10:00:00-06:00", "document_id": 33380, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/33380.pdf", "status_text": "Do Pass", "journal_page": 74, "committee_id_action": 264, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 17565, "president_vote": null, "Yea": [853, 943, 899, 901, 902, 872, 880]}}, {"bill_id": 6403, "action_date": "2015-01-22T14:00:00-06:00", "document_id": 33508, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/33508.pdf", "status_text": "Do Pass", "journal_page": 94, "committee_id_action": 284, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 17641, "president_vote": null, "Yea": [853, 854, 855, 856, 858, 860, 889, 894, 903, 876, 899, 885, 896, 901, 895, 898, 890, 900, 942, 891, 893, 886, 862, 880, 944, 902, 877, 868, 871, 892, 872, 873, 878, 897], "Excused": [943]}}, {"bill_id": 6403, "action_date": "2015-01-23T13:00:00-06:00", "document_id": 33597, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/33597.pdf", "status_text": "First read in House and referred to", "journal_page": 125, "committee_id_action": 286, "committee_id_assigned": 275, "result": "N", "vote": {}}, {"bill_id": 6403, "action_date": "2015-01-29T07:45:00-06:00", "document_id": 33650, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/33650.pdf", "status_text": "Scheduled for hearing", "journal_page": 0, "committee_id_action": 275, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 6403, "action_date": "2015-01-29T07:45:00-06:00", "document_id": 34063, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34063.pdf", "status_text": "Do Pass", "journal_page": 223, "committee_id_action": 275, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 17905, "president_vote": null, "Yea": [928, 923, 941, 929, 948, 909, 958, 930, 926, 955, 934, 946, 881]}}, {"bill_id": 6403, "action_date": "2015-01-30T13:00:00-06:00", "document_id": 34236, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34236.pdf", "status_text": "Deferred to another day", "journal_page": 252, "committee_id_action": 286, "committee_id_assigned": null, "result": "P", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-03T14:00:00-06:00", "document_id": 34394, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34394.pdf", "status_text": "Deferred to another day", "journal_page": 276, "committee_id_action": 286, "committee_id_assigned": null, "result": "P", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-04T14:00:00-06:00", "document_id": 34477, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34477.pdf", "status_text": "Deferred to another day", "journal_page": 298, "committee_id_action": 286, "committee_id_assigned": null, "result": "P", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-05T14:00:00-06:00", "document_id": 34567, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34567.pdf", "status_text": "Deferred to another day", "journal_page": 316, "committee_id_action": 286, "committee_id_assigned": null, "result": "P", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-06T13:00:00-06:00", "document_id": 34653, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34653.pdf", "status_text": "Deferred to another day", "journal_page": 333, "committee_id_action": 286, "committee_id_assigned": null, "result": "P", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-09T14:00:00-06:00", "document_id": 34730, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34730.pdf", "status_text": "Deferred to another day", "journal_page": 353, "committee_id_action": 286, "committee_id_assigned": null, "result": "P", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-10T14:00:00-06:00", "document_id": 34820, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34820.pdf", "status_text": "Do Pass", "journal_page": 370, "committee_id_action": 286, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 18500, "president_vote": null, "Yea": [883, 915, 952, 884, 938, 888, 928, 923, 925, 875, 931, 941, 927, 857, 859, 917, 924, 929, 947, 937, 948, 945, 882, 909, 946, 958, 913, 887, 951, 861, 919, 956, 936, 879, 907, 939, 920, 930, 953, 881, 908, 940, 935, 916, 911, 910, 863, 864, 914, 922, 933, 866, 867, 926, 955, 869, 950, 912, 904, 918, 954, 932, 949, 934, 957, 874], "Nay": [905], "Excused": [906, 865, 921]}}, {"bill_id": 6403, "action_date": "2015-02-11T14:00:00-06:00", "document_id": 34923, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/34923.pdf", "status_text": "Signed by the President", "journal_page": 381, "committee_id_action": 284, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-12T13:00:00-06:00", "document_id": 35007, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/35007.pdf", "status_text": "Signed by the Speaker", "journal_page": 402, "committee_id_action": 286, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-17T14:00:00-06:00", "document_id": 35120, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/35120.pdf", "status_text": "Delivered to the Governor", "journal_page": 404, "committee_id_action": 284, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 6403, "action_date": "2015-02-18T14:30:00-06:00", "document_id": 35199, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/35199.pdf", "status_text": "Signed by the Governor", "journal_page": 426, "committee_id_action": 284, "committee_id_assigned": null, "result": "N", "vote": {}}], "session_law": 5937, "rss_feed": "https://sdlegislature.gov/api/Bills/RSS/6403"}